Providing Targeted Cancer Diagnostics


Advanced Diagnostics Begins Centralised Testing for Major Clinical Trial.

'Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis.'  OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'.

Advanced Diagnostics role within OPTIMA trial is to ensure centralised testing of Oestrogen Receptor (ER) and Human Epidermal Growth Factor Receptor-2  (HER2) gene status as well as additional preparative methods for molecular analysis.  The selection of HSL-AD as the central testing lab for OPTIMA greatly enhances HSL-AD's portfolio of active clinical trials.